Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Pantoprazole in ICU patients at risk for gastrointestinal bleeding-1-year mortality in the SUP-ICU trial

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Inadequate emergence after non-cardiac surgery-A prospective observational study in 1000 patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Time to onset of gastrointestinal bleeding in the SUP-ICU trial: a preplanned substudy

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Use of red blood cells in Danish intensive care units: A population-based register study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Heterogeneity of treatment effect of stress ulcer prophylaxis in ICU patients: A secondary analysis protocol

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Storage time of red blood cells among ICU patients with septic shock

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: The long-term effects of stress ulcer prophylaxis with pantoprazole are unknown in ICU patients. We report 1-year mortality outcome in the Stress Ulcer Prophylaxis in the Intensive Care Unit (SUP-ICU) trial.

METHODS: In the SUP-ICU trial, acutely admitted adult ICU patients at risk of gastrointestinal bleeding were randomised to intravenous pantoprazole 40 mg vs placebo (saline) once daily during their ICU stay. We assessed mortality at 1 year and did sensitivity analyses according to the trial protocol and statistical analysis plan.

RESULTS: A total of 3261 of the 3291 patients with available data (99.1%) were followed up at 1 year after randomisation; 1635 were allocated to pantoprazole and 1626 to placebo. At 1 year after randomisation, 610 of 1635 patients (37.3%) had died in the pantoprazole group as compared with 601 of 1626 (37.0%) in the placebo group (relative risk, 1.01; 95% confidence interval 0.92-1.10). The results were consistent in the sensitivity analysis adjusted for baseline risk factors and in those of the per-protocol population. We did not observe heterogeneity in the effect of pantoprazole vs placebo on 1-year mortality in the predefined subgroups, that is, patients with and without shock, mechanical ventilation, liver disease, coagulopathy, high disease severity (SAPS II > 53) or in medical vs surgical ICU patients.

CONCLUSION: We did not observe a difference in 1-year mortality among acutely admitted adult ICU patients with risk factors for gastrointestinal bleeding allocated to stress ulcer prophylaxis with pantoprazole or placebo during the ICU stay. (The SUP-ICU trial was funded by Innovation Fund Denmark and others; ClinicalTrials.gov number, NCT02467621).

Original languageEnglish
JournalActa Anaesthesiologica Scandinavica
Volume63
Issue number9
Pages (from-to)1184-1190
ISSN0001-5172
DOIs
Publication statusPublished - 8 Jul 2019

ID: 57626471